Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTo qualify for Wegovy in the UK, you need a BMI of 30 or above, or a BMI of 27 or above if you also have at least one weight-related health condition such as high blood pressure, type 2 diabetes or high cholesterol. BMI alone doesn't guarantee a prescription — a prescriber assesses your full medical picture. Wegovy (semaglutide) is a prescription-only medicine; no one can be approved without a clinical assessment first. If you're close to a threshold or unsure where you sit, the NHS BMI calculator gives you an instant reading to bring to that conversation.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture this: you've just typed your height and weight into a BMI calculator, the number comes back at 28.4, and you're wondering if that's enough. The answer depends on whether you also have a qualifying health condition. If you want to understand what does BMI need to be for Wegovy in practical terms, the UK licence covers adults with a BMI of 30 or above outright. Below that, a BMI of 27 to 29.9 qualifies if a prescriber confirms at least one weight-related condition alongside it, common examples include high blood pressure, raised cholesterol, obstructive sleep apnoea, prediabetes and type 2 diabetes.
One misconception worth clearing up gently: many people assume the 30 threshold is a hard wall and that 29.9 means an automatic no. It isn't quite that simple. If you sit in the 27–29.9 band and have a relevant condition, you genuinely do meet the licensed criteria, and a prescriber will consider you. The broader eligibility picture for Wegovy covers more of those conditions in detail if you want to check yours against the list.
It is also worth knowing that lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance, specifically 2.5 kg/m² below the standard figures for South Asian, Chinese, Middle Eastern, Black African and African-Caribbean backgrounds. You can read about which BMI figures qualify for Wegovy across all these scenarios, including how the adjusted ethnic-background thresholds work in practice. A common question is what BMI do I need for Wegovy when those adjusted thresholds apply, and the short answer is that a BMI of 27.5 with a relevant condition could be enough for someone whose background meets that criterion. This is something a prescriber will factor in, not something you need to calculate yourself.
NHS access to Wegovy sits under NICE's technology appraisal TA875, and the criteria are notably tighter than the licensed thresholds above. On the NHS, Wegovy is only recommended through a specialist weight management service, with multidisciplinary support, for adults with a BMI of 35 or above and at least one weight-related comorbidity. The treatment is also time-limited to a maximum of two years. If weight loss falls below 5% after six months at the full maintenance dose, NICE guidance says continuing should be reconsidered.
Waiting lists for those specialist services can stretch for a long time in many areas, and not everyone meets the NHS BMI threshold even if they qualify under the licensed criteria. A private route through a regulated pharmacy is the realistic alternative for most people who want to start sooner or who sit between the licensed and NHS thresholds. You can see what private Wegovy treatment involves, including what a single transparent price covers, on the Wegovy cost page.
Scotland, Wales and Northern Ireland operate separate commissioning frameworks, so availability through the NHS varies further by nation. If you're specifically asking what BMI do I need to get Wegovy through the private licensed route, this breakdown covers the thresholds side by side.
A BMI that meets the threshold opens the conversation; it doesn't close it. A prescriber reviewing a Wegovy consultation will also look at your current medicines, your medical history and any contraindications listed in the prescribing information. Semaglutide is not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive. It is not licensed for under-18s. A personal or family history of medullary thyroid carcinoma, or a condition called MEN2, rules it out entirely, these are listed formally in the NHS patient information on semaglutide.
Certain gastrointestinal conditions and a history of pancreatitis also require careful prescriber discussion before treatment can go ahead. None of this means those situations are automatically a barrier; it means the prescriber needs the full picture. That is exactly why Wegovy requires a clinical assessment rather than a straightforward purchase, and why the consultation exists.
At nume, every consultation is read personally by a GPhC-registered Independent Prescriber on the same day, not processed by an algorithm. If you'd like to talk through your BMI, your health history and what you need to qualify, speaking to our prescribers starts with a free consultation. Our clinical team's approach to assessment is outlined on the clinical team page if you'd like to know more about who reviews your case.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.